Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
" ^. D, ~: `9 Z3 k- w4 ?3 ~9 e' Q# @/ j( k2 u- a
- |4 w2 j' c7 R& P
Sub-category:' l& e$ ]& \+ y! h. |
Molecular Targets
: a0 M; C# J1 U2 n* l& }! ?* G5 s) H! d$ |0 N
" p, K+ w9 C& f' M; S
Category:8 Z/ U% V$ N0 z0 E, k: v* @5 G$ l
Tumor Biology ) s6 h* r& e+ b- Q
8 v* ? m8 G+ D5 P! o5 o* b4 i+ k1 ?0 e" W$ Z3 _' n& n- M& b
Meeting:
# R* W* z+ z% O0 _; w2011 ASCO Annual Meeting
1 l$ a7 {# J' D1 j5 S0 H9 [; T: Z# }) r! d" Y) ~
& l: {0 c# V/ Z/ ^# ^
Session Type and Session Title:+ Z4 F9 t" o7 n: t
Poster Discussion Session, Tumor Biology ' l4 @4 k; r: G. | X* Z
$ H( R* Y# K" @) s$ T0 x; @5 g; D: x+ r
Abstract No:
. b5 M: O4 |+ R8 j% u6 |/ A$ }10517
: z6 d% _$ ^" z8 v5 P |& S/ A1 y3 \+ v% u: R0 R) ?
1 s% s* G- }1 l9 G4 z
Citation:: b% X' A* R( e
J Clin Oncol 29: 2011 (suppl; abstr 10517) & Z s. X, d( g. F) B7 j
- L. H; e! s! B- I: X' E! @
% }8 E2 J2 ^* N9 {Author(s):, r; i6 ^- f* j5 b. Y f
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
7 J+ `4 u) {! c' }0 W v1 l. k# ` E; Z8 s+ R: T1 P
" g) s- A3 N: A- B9 o- v) O/ V
/ ]# n- u5 Z# Y- \3 a: ]
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
8 i4 x- E4 u1 P$ K" a' e& U; M2 r8 U" k8 b
Abstract Disclosures
: ?4 c1 J( D" U# f7 e; l6 j F; G5 Y4 g9 H/ D% b/ f5 S
Abstract:
6 J" ]+ W' B$ x% u8 {1 K8 I
2 W8 Z& J4 V& i0 p! n2 ~' p' q( u- s% N! o- m
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
4 k0 T' k$ j- G+ _: v# {/ F) d
: o. H+ O/ c; s/ M
' b! F/ b1 u8 k* j# G8 H( O6 o) f$ V& N/ Q |
# T4 ^* r9 \. t- k
显身卡
